Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma.
Wong Michael K, Bowers Mallory E, Ventimiglia Jonas, Niknam Rachel M, Moster Marlene R, Pro Michael J, Dale Elizabeth, Kolomeyer Natasha N, Lee Daniel, Zheng Cindy X
AI Summary
This study found intracameral Bimatoprost SR significantly lowered IOP and medication use in glaucoma patients, offering an effective treatment option even after prior SLT.
Abstract
Précis: This retrospective study found a statistically significant reduction in mean intraocular pressure (IOP) and the number of medications after intracameral Bimatoprost sustained release (SR) injection in patients with glaucoma. A history of selective laser trabeculoplasty (SLT) did not impact treatment outcomes.
Purpose
To determine outcomes of Bimatoprost SR on IOP and the number of topical IOP-lowering medications in patients with glaucoma. A secondary objective was to determine the outcomes of Bimatoprost SR in patients with a prior history of SLT.
Methods
Retrospective case series. One hundred eighteen eyes from 84 patients that received Bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital from March 2020 to September 2021 were examined. The intervention was a single injection of intracameral Bimatoprost SR. The main outcome measures included IOP and the number of medications.
Results
The most recent mean follow-up time for all eyes was 27.8 ± 18.6 weeks. The mean posttreatment IOP at the most recent follow-up of 16.6 ± 5.3 mm Hg was significantly lower than the mean under-therapy pretreatment IOP of 18.5 ± 5.7 mm Hg for all eyes ( P < 0.01). The mean posttreatment number of medications at the most recent follow-up of 1.3 ± 1.3 decreased compared with the number of pretreatment medications of 2.1 ± 1.4 for all eyes ( P < 0.01). Analysis of multilevel models controlling for demographic variables demonstrated a statistically significant reduction in IOP and number of medications posttreatment ( P < 0.01). A prior history of SLT (n = 54) had no impact on treatment for both IOP and the number of medications ( P > 0.1 for both).
Conclusions
Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.
MeSH Terms
Shields Classification
Key Concepts3
In patients with glaucoma, a single intracameral injection of Bimatoprost sustained release (SR) significantly reduced the mean intraocular pressure (IOP) from 18.5 5.7 mm Hg pretreatment to 16.6 5.3 mm Hg posttreatment (P < 0.01) at a mean follow-up of 27.8 18.6 weeks.
In patients with glaucoma, a single intracameral injection of Bimatoprost sustained release (SR) significantly decreased the mean number of topical IOP-lowering medications from 2.1 1.4 pretreatment to 1.3 1.3 posttreatment (P < 0.01) at a mean follow-up of 27.8 18.6 weeks.
A prior history of selective laser trabeculoplasty (SLT) in patients with glaucoma (n = 54) had no impact on the treatment outcomes of intracameral Bimatoprost sustained release (SR) for both intraocular pressure (IOP) and the number of medications (P > 0.1 for both).
Related Articles5
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
Randomized Controlled TrialThe Impact of Baseline Intraocular Pressure on Initial Treatment Response in the LiGHT Trial: Selective Laser Trabeculoplasty versus Medication.
Randomized Controlled TrialEffect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty.
Randomized Controlled TrialInitial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study.
Randomized Controlled TrialPrevention of the immediate intraocular pressure rise following argon laser trabeculoplasty.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.